GSK wins regulatory boost for once-monthly liver drug efimosfermin in MASH push

The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights

Pfizer locks in long runway for blockbuster heart drug after key patent settlements

The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026

US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

GE HealthCare expands DeepHealth AI partnership to supercharge breast cancer detection

The move aims to accelerate the development, commercialization, and global rollout of advanced AI-powered mammography tools

Galderma rolls out next-generation regenerating skin nectar

Merck bags EU nod for infant RSV protection in major public health milestone

ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose